Common brain tumor drug put to the test: does it worsen diabetes risk?
NCT ID NCT07045935
Summary
This study aims to see if different treatment approaches with the standard drug cabergoline affect blood sugar and insulin levels in people with prolactinoma, a common benign pituitary tumor. It will enroll 60 adults who are either newly diagnosed or already on stable treatment. Researchers will compare how two different treatment strategies impact glucose metabolism over one year using standard blood sugar tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLACTINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel, Dept. of Endocrinology, Metabolism & Diabetes
RECRUITINGBasel, 4031, Switzerland
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.